Having recently completed an expansion in Hungary, anti-infectives specialist Xellia Pharmaceuticals is moving on to a project at its headquarters site in Denmark.
The company says it will invest about $25 million to build a new sterile manufacturing facility at its site in Copenhagen where it produces, tests and packages both sterile APIs and the finished dosage forms of the company’s anti-infectives such as vancomycin and colistmethate sodium.
A spokesperson said in an email that the project is an upgrade rather than an expansion and that the new facility will have isolator technology to ensure future compliance and meet the most stringent regulatory standards. It will be capable of processing more than 40 tons of sterile APIs.
No new jobs will stem from the project, she said, but the site, the company's largest, currently has about 600 employees.
The project comes on the heels of several other production upgrades around Xellia's global manufacturing network. In August, it completed a $13 million, 3,000-square-meter lab next to an API manufacturing facility at its Budapest, Hungary, site.
It is also reworking the former Boehringer Ingelheim plant in Bedford, Ohio, and expects to get it back into production next year. Xellia acquired the facility in a 2015 deal with Hikma, which in turn got it from Boehringer Ingelheim.
The German company closed the long-troubled manufacturing site in 2013, laying off more than 1,000 employees, after deciding the potential payback of revamping the facilities to comply with an FDA consent decree was not worth the cost. It had already invested about $350 million in upgrades at that point. The FDA modified the consent decree last year, laying out what Xellia needed to do to get the specific facilities it acquired back online.